跳至主要内容
临床试验/NCT07323017
NCT07323017进行中(未招募)不适用

Electrochemotherapy in Musculoskeletal Tumors: A Quantitative Assessment of Tumor Size Variations and Treatment-related Pain Reduction.

Costantino Errani1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年8月1日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
60
试验地点
1
主要终点
Tumor size will be assessed using CT, MRI, X-ray, and/or PET imaging. Tumor size will be defined as the longest diameter of the target lesion (mm).

研究概览

简要总结

The study involves the enrollment of patients over 2 years of age with a diagnosis of musculoskeletal tumors and an indication for electrochemotherapy, treated at the Rizzoli Orthopaedic Institute in Bologna and followed during outpatient follow-up. Data will be collected from medical records, outpatient reports, and imaging studies including CT, X-ray, MRI, and/or PET.

For the retrospective part of the study, patients treated at the Rizzoli Orthopaedic Institute from 01/01/2024 to the date of approval of this study will be included. For the prospective part, patients meeting the inclusion criteria and treated from the study start date until 31/12/2030 will be enrolled.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients of both sexes with a histological diagnosis of a primary musculoskeletal tumor, either benign or malignant, located outside the abdominal cavity (trunk and limbs)
  • Indication for electrochemotherapy due to one of the following conditions:
  • Clinical conditions contraindicating surgery
  • Tumor not surgically resectable
  • Patients treated with electrochemotherapy at the Rizzoli Orthopaedic Institute:
  • From 01/01/2024 to the date of study approval for the retrospective phase
  • From the date of study approval to 12/31/2030 for the prospective phase
  • Retrospectively treated patients with a minimum follow-up of at least 3 months
  • Age ≥ 2 years at the time of treatment
  • Availability of clinical and instrumental data

排除标准

  • Failure to meet at least one of the inclusion criteria

结局指标

主要结局

Tumor size will be assessed using CT, MRI, X-ray, and/or PET imaging. Tumor size will be defined as the longest diameter of the target lesion (mm).

时间窗: 3, 6, and 12 months after electrochemotherapy

次要结局

  • Change from baseline in pain intensity measured by the Visual Analog Scale (VAS), ranging from 0 to 10, where higher scores indicate worse pain, at 3, 6, and 12 months after electrochemotherapy.Number of participants with treatment-related adverse events(3, 6, and 12 months after treatment)

研究者

发起方
Costantino Errani
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Costantino Errani

Principal Investigator

Istituto Ortopedico Rizzoli

研究点 (1)

Loading locations...

相似试验